Sulfamethoxazole-Trimethoprim Dosing for Adult UTI with Renal Impairment

Standard Dosing by Clinical Scenario

The American College of Physicians recommends a standard dose of 160/800 mg (one double-strength tablet) twice daily for 3 days for uncomplicated cystitis in women, with clinical cure rates of 90-100% when organisms are susceptible 2, 3
For UTI in men, considered complicated, the standard dose is 160/800 mg twice daily for 7-14 days, as the 3-day regimen used in women is inadequate for male patients 1
The Infectious Diseases Society of America recommends a standard dose of 160/800 mg twice daily for 14 days for complicated UTI or pyelonephritis, only after confirming susceptibility testing 4

The National Kidney Foundation recommends using the standard dose of 160/800 mg twice daily for patients with creatinine clearance >30 mL/min 1
For patients with creatinine clearance 15-30 mL/min, the dose should be reduced to half-dose: 80/400 mg (one single-strength tablet) twice daily 1

The American Society of Nephrology recommends obtaining baseline creatinine clearance calculation before initiating therapy, and monitoring serum creatinine and BUN 2-3 times weekly during therapy in patients with renal impairment 1
Regular monitoring of electrolytes is also recommended, as trimethoprim blocks potassium excretion and can cause hyperkalemia 1

The Centers for Disease Control and Prevention recommend only using trimethoprim-sulfamethoxazole empirically when local E. coli resistance is <20% 2, 3, 4
The clinical cure rate drops from 84% (susceptible organisms) to only 41% (resistant organisms), and treatment failure is the expected outcome when organisms are resistant 3, 4

The European Society of Clinical Microbiology and Infectious Diseases recommends nitrofurantoin monohydrate/macrocrystals: 100 mg twice daily for 5 days, with a clinical cure rate of 90% and bacterial cure rate of 92% 1, 4
Fosfomycin trometamol: 3g single dose, and pivmecillinam: 400 mg three times daily for 3-5 days, are also recommended as alternative first-line agents 1

The American College of Obstetricians and Gynecologists recommends avoiding trimethoprim-sulfamethoxazole in the last trimester of pregnancy, and using it with caution in the second trimester 1, 4

The patient should be counseled about the risk of rash and urticaria, nausea and vomiting, and rare but serious adverse effects such as Stevens-Johnson syndrome 4, 5

The patient's treatment plan should never use a 3-day regimen for male patients, as this is inadequate treatment and leads to treatment failure 1
The dose should never be failed to be adjusted when CrCl <30 mL/min, as this significantly increases toxicity risk including hyperkalemia and crystalluria 1
Trimethoprim-sulfamethoxazole should never be used empirically when local resistance exceeds 20%, as treatment failure outweighs benefits 4